QSS
AVDL

Quantitative Systematic Strategies’s Avadel Pharmaceuticals AVDL Stock Holding History

Quantitative Systematic Strategies’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-27,630
Closed -$139K – 611
2020
Q3 		$139K Buy
27,630
+434
+2% +$3.16K 0.02% 549
2020
Q2 		$220K Buy
+27,196
New +$240K 0.04% 492
2018
Q4 		– Sell
-12,985
Closed -$57K – 694
2018
Q3 		$57K Sell
12,985
-12,296
-49% -$66.4K 0.01% 596
2018
Q2 		$155K Buy
25,281
+12,661
+100% +$88.8K 0.03% 574
2018
Q1 		$92K Buy
+12,620
New +$111K 0.02% 601
2016
Q3 		– Sell
-24,232
Closed -$261K – 377
2016
Q2 		$261K Buy
+24,232
New +$258K 0.12% 226
2016
Q1 		– Sell
-18,070
Closed -$262K – 437
2015
Q4 		$262K Sell
18,070
-18,261
-50% -$285K 0.07% 805
2015
Q3 		$611K Buy
+36,331
New +$800K 0.3% 117
2015
Q2 		– Sell
-22,198
Closed -$400K – 509
2015
Q1 		$400K Buy
+22,198
New +$348K 0.11% 261

Other funds holding AVDL

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ACM
Asymmetry Capital Management San Francisco, California $188M AUM 44.72% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

Quantitative Systematic Strategies's AVDL Position: Q4 2020 in Review

Quantitative Systematic Strategies sold out of Avadel Pharmaceuticals (AVDL) in Q4 2020, closing a stake of 27,630 shares — an estimated $139K sold.

Quantitative Systematic Strategies first reported a position in AVDL in Q1 2015 and held it in 9 quarters. The position peaked at $611K in Q3 2015. 82 funds tracked by Wall St. Rank hold AVDL as of Q4 2020.

  • Quantitative Systematic Strategies reported no remaining Avadel Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Quantitative Systematic Strategies sold 27,630 Avadel Pharmaceuticals shares in Q4 2020, an estimated $139K.
  • Quantitative Systematic Strategies first reported a position in Avadel Pharmaceuticals in Q1 2015 and held it in 9 quarters.
  • Quantitative Systematic Strategies's Avadel Pharmaceuticals position peaked at $611K in Q3 2015.
  • 82 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q4 2020.

Based on Quantitative Systematic Strategies's 13F filing for Q4 2020, filed 9 Feb 2021.